<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04287400</url>
  </required_header>
  <id_info>
    <org_study_id>2018-0428-0001</org_study_id>
    <nct_id>NCT04287400</nct_id>
  </id_info>
  <brief_title>Prospective Trial for the Evaluation of Radiogenomics in Advanced Rectal Cancer</brief_title>
  <official_title>Prospective Clinical Trial for the Evaluation of Radiogenomics: Correlation, Treatment Response and Prognosis in Patients With Advanced Rectal Cancer, Who Undergo Preoperative Chemoradiation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients with advanced rectal cancer, molecular subtypes will be identified by
      preoperative biopsy, CT, MRI / PET radiomics analysis, clinical features, and clinical
      features will be confirmed and compared.

      Also, we want to confirm the relationship between these factors and the treatment response
      after chemoradiotherapy before surgery. The prognosis will be then assessed through 5-year
      overall survival and 3-year disease free survival.

      A prospective clinical trial, recruiting 210 persons (approximately 53 per year) that meet
      the selection criteria for approximately four years from the IRB approval date in 2019 (about
      53 per year) We will analyze the data and then collect and analyze the data and report the
      results.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 5, 2019</start_date>
  <completion_date type="Anticipated">February 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>K-RAS Mutation</measure>
    <time_frame>4 weeks</time_frame>
    <description>K-RAS Mutation status</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiomics - MR image findings</measure>
    <time_frame>4 weeks</time_frame>
    <description>Radiologic features</description>
  </secondary_outcome>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Rectal Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Endoscopic cancer biopsy before starting treatment
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with mid-lower rectal cancer and expected to receive chemoradiotherapy
        before surgery
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 20-80 years

          -  Patients diagnosed with mid-lower rectal cancer and expected to receive
             chemoradiotherapy before surgery

        Exclusion Criteria:

          -  Patients with distal metastases confirmed at diagnosis

          -  Patients with other bowel diseases such as IBD, ischemic colitis and TB colitis in
             addition to colorectal cancer

          -  If patients do not agree with this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>DAE KYUNG SOHN</last_name>
    <phone>82319201636</phone>
    <email>gsgsbal@ncc.re.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dae Sohn</last_name>
    <phone>82319201282</phone>
    <email>gsgsbal@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dae Kyung Sohn, MD,PHD</last_name>
      <phone>+82‐31‐920‐1636</phone>
      <email>gsgsbal@ncc.re.kr</email>
    </contact>
    <contact_backup>
      <last_name>Dae Kyung Sohn</last_name>
      <phone>+82‐31‐920‐1761</phone>
      <email>gsgsbal@ncc.re.kr</email>
    </contact_backup>
    <investigator>
      <last_name>Dae Kyung Sohn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 26, 2019</study_first_submitted>
  <study_first_submitted_qc>February 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2020</study_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Center, Korea</investigator_affiliation>
    <investigator_full_name>Dae Kyung Sohn</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

